Goldman Sachs Reaffirms Novo Nordisk Target
Goldman Sachs keeps $47 target on Novo Nordisk stock Goldman Sachs has reaffirmed its Neutral rating and $47 price target on Novo Nordisk stock after meeting management at a healthcare conference. The bank had lifted that target to $47 from $41 on June 3, so the confe